Aby wyświetlić tę treść, wymagana jest subskrypcja JoVE. Zaloguj się lub rozpocznij bezpłatny okres próbny.
Method Article
* Wspomniani autorzy wnieśli do projektu równy wkład.
This method describes the placement of interposition vein grafts in rabbits, the transduction of the grafts, and the achievement of durable transgene expression. This allows the investigation of physiological and pathological roles of transgenes and their protein products in grafted veins, and testing of gene therapies for vein graft disease.
Vein graft bypass surgery is a common treatment for occlusive arterial disease; however, long-term success is limited by graft failure due to thrombosis, intimal hyperplasia, and atherosclerosis. The goal of this article is to demonstrate a method for placing bilateral venous interposition grafts in a rabbit, then transducing the grafts with a gene transfer vector that achieves durable transgene expression. The method allows the investigation of the biological roles of genes and their protein products in normal vein graft homeostasis. It also allows the testing of transgenes for the activities that could prevent vein graft failure, e.g., whether the expression of a transgene prevents the neointimal growth, reduces the vascular inflammation, or reduces atherosclerosis in rabbits fed with a high-fat diet. During an initial survival surgery, the segments of right and left external jugular vein are excised and placed bilaterally as reversed end-to-side common carotid artery interposition grafts. During a second survival surgery, performed 28 days later, each of the grafts is isolated from the circulation with vascular clips and the lumens are filled (via an arteriotomy) with a solution containing a helper-dependent adenoviral (HDAd) vector. After a 20-min incubation, the vector solution is aspirated, the arteriotomy is repaired, and flow is restored. The veins are harvested at time points dictated by individual experimental protocols. The 28-day delay between the graft placement and the transduction is necessary to ensure the adaptation of the vein graft to the arterial circulation. This adaptation avoids rapid loss of transgene expression that occurs in vein grafts transduced before or immediately after grafting. The method is unique in its ability to achieve durable, stable transgene expression in grafted veins. Compared to other large animal vein graft models, rabbits have advantages of low cost and easy handling. Compared to rodent vein graft models, rabbits have larger and easier-to-manipulate blood vessels that provide abundant tissue for analysis.
Atherosclerosis is a chronic inflammatory disease in which lipid accumulation and inflammation in the blood vessel wall lead to narrowing of the vessel lumen, heart attacks, strokes, and loss of limbs1,2. Percutaneous interventions (e.g., angioplasty and stenting) and medical therapy (e.g., statins and antiplatelet agents) are useful treatments for atherosclerosis; however, they are often ineffective in treating severe obstructive disease both in the coronary and peripheral circulations. Bypass grafting, using autogenous vein segments, remains a common procedure for treating patients with severe, diffuse coronary and peripheral vascular disease3,4. However, vein grafts placed in both the coronary and peripheral circulations have poor long-term patency rates. In the coronary circulation, approximately 10-20% of vein grafts are occluded at 1 year and 50% are occluded by 10 years5,6.In the peripheral circulation, vein graft failure rates are 30-50% at 5 years7.
Gene therapy is an attractive approach for the prevention of vein graft failure because it can deliver a therapeutic gene product precisely at the site of the disease. Accordingly, numerous preclinical studies have tested vein graft gene therapy8,9. However, essentially all of these studies have examined the efficacy at early time points (2-12 weeks)10,11,12,13,14,15,16,17. We are aware of no evidence that gene-therapy interventions can provide durable (years) protection against late vein graft failure that typically results from neointimal hyperplasia and atherosclerosis4. We developed a method that allows durable transgene expression in grafted veins, and thereby allows the testing of gene-therapy interventions at late as well as early time points. To achieve durable transgene expression, the method incorporates HDAd vectors and a delayed transduction strategy. HDAd vectors provide prolonged transgene expression because they lack viral genes, preventing the recognition (and rejection) of transduced cells by the immune system18,19,20,21. Delayed transduction (performed 28 days after the graft placement) prevents the loss of transduced cells during the arterialization process that occurs early after the grafting22.
Other methods that achieve therapeutic transgene expression in the vein graft wall rely on the transduction of the vein graft at the time of the graft placement10,11,12,15,16,17. When measured serially, transgene expression using this approach declines quickly after the transduction22,23. Accordingly, studies using this approach have not examined the efficacy beyond 12 weeks after the vein grafting, with most not assessing efficacy beyond 4 weeks. In contrast, our method achieves vein graft transgene expression that persists stably for at least 24 weeks and-based on similar studies performed in arteries-likely continues far longer22,24. We are aware of no other vein graft gene therapy intervention that achieves stable transgene expression of this duration.
We used a rabbit model to develop our method. Others have used rodents, rabbits, or larger animals to test vein graft gene therapy10,11,12,15,16,17,25,26. Compared to rodent models, rabbits are more expensive and are subject to more stringent regulatory requirements. However, compared to larger animals (e.g., pigs and dogs), rabbits are far less expensive to purchase and house and much easier to handle. Moreover, rabbit vessels resemble human vessels physiologically27, they are sufficiently large that they can be used for testing percutaneous interventions28,29, and they provide sufficient tissue that multiple endpoints (e.g., histology, protein, RNA) can be examined using a single blood vessel specimen22,30. In addition, when the rabbits with vein grafts are fed with a high-fat diet, they develop vein graft atherosclerosis31,32, which is a common cause of coronary artery bypass vein graft failure4,5. These atherosclerotic rabbit vein grafts can serve as a substrate for testing gene-therapy interventions delivered with this method. The provided protocol can help investigators to master the technical skills required to achieve durable transgene expression in rabbit vein grafts.
All animal protocols and studies were approved by the University of Washington Office of Animal Welfare.
1. Pre-operation (for All Surgeries)
2. Vein Graft Surgery (Survival)
3. Transcutaneous Ultrasound
4. Gene Transfer Surgery Performed ~ 28 Days After the Graft Placement (Survival Surgery)
5. Harvest Surgery (Terminal)
The technical proficiency of a new operator must be validated before the operator can use this method to generate experimental data. The first milestone that a new operator must achieve is consistent vein graft patency after both the initial vein-grafting surgery and the subsequent delayed-transduction surgery. Over 90% patency after each of the surgeries is desirable and achievable. The patency can be assessed non-invasively using transcutaneous ultrasound, which we typically perform on ...
Critical steps in this protocol include the management of anesthesia, anticoagulation, surgical manipulation of the artery/grafted vein, and hemodynamic measurements of the grafted vein. Proper management of anesthesia is critical in this multiple survival surgery model that includes two relatively long operations (typically 3-3.5 h for bilateral vein grafting and 1.5-2.5 h for bilateral graft transduction). We have administered anesthesia both via a nosecone and by endotracheal intubation and found that the intubation i...
The authors have nothing to disclose.
Name | Company | Catalog Number | Comments |
Disposables | |||
3mL syringe with 24G needle | Becton Dickinson | 309571 | 2x for vein graft surgery; 2x for gene transfer surgery |
1 mL syringe with 27G needle | Becton Dickinson | 309623 | 2x for vein graft surgery, 5x for gene transfer surgery |
19G needle | Becton Dickinson | 305187 | Gene transfer surgery |
20 mL syringe, luer lock | Nipro Medical Corp | JD+20L | |
Catheters, 24Ga x 3/4” | Terumo Medical Products | SROX2419V | |
21G needle | Becton Dickinson | 305165 | Gene transfer surgery and for 20 mL syringe of saline |
Gauze 4” x 4” | Dynarex | 3242 | ~10-15 per surgery |
3-0 silk suture | Covidien Ltd. | S-244 | |
5-0 silk suture | Covidien Ltd. | S-182 | |
7-0 polypropylene suture | CP Medical | 8703P | Vein graft surgery |
7-0 polypropylene suture | CP Medical | 8648P | Gene transfer surgery |
5-0 polyglycolic acid suture | CP Medical | 421A | |
3-0 polyglycolic acid suture | CP Medical | 398A | |
Alcohol swabs | Covidien Ltd. | 6818 | For the placement of I.V. line |
Catheter plug | Vetoquinol | 411498 | |
Ketamine HCl, 100 mg/mL | Vedco Inc. | 5098916106 | |
Xylazine, 100 mg/mL | Akorn Inc. | 4821 | |
Lidocaine, 20 mg/mL | Pfizer | 409427702 | |
Marcaine 0.5% | Pfizer | 409161050 | |
Beuthanasia D-Special | Intervet Inc. | NDC 00061047305 | Harvest surgery only |
Buprenorphine HCl, 0.3 mg/mL | Patterson Veterinary | 12496075705 | |
Saline IV bag, 0.9% sodium chloride | Baxter | 2B1309 | |
Heparin (5000 U/mL) | APP Pharmaceuticals | NDC 63323-047-10 | |
Papaverine (3.5 mg/ml) | American Reagent Inc. | NDC 0517-4002-25 | Diluted from 30mg/mL stock; Use 1 mL maximum |
Fentanyl patch, 25 mcg/h | Apotex Corp. | NDC 60505-7006-2 | |
Isoflurane | Multiple vendors | Catalog number not available | |
Viral vector | Gene transfer surgery only | ||
Surgical Instruments | |||
Metzenbaum needle holder 7" straight | Roboz | RS-7900 | |
Operating scissors 6.5" straight blunt/blunt | Roboz | RS-6828 | |
Needle holder /w suture scissors | Miltex | 8-14-IMC | |
Castroviejo scissors | Roboz | RS-5658 | |
Castroviejo needle holder, 5.75" straight with lock | Roboz | RS-6412 | |
Stevens scissors 4.25" curved blunt/blunt | Roboz | RS-5943 | |
Alm retractor 4" 4X4 5mm blunt prongs | Roboz | RS-6514 | 2x |
Backhaus towel clamp 3.5" | Roboz | 4x | |
Micro clip setting forceps 4.75" | Roboz | RS-6496 | |
Micro vascular clips, 11 mm | Roboz | ||
Surg-I-Loop | Scanlan International | 1001-81M | 5 cm length |
Bonaccolto forceps, 4” (10 cm) long longitudinal serrations, cross serrated tip, 1.2mm tip width | Roboz | RS-5210 | |
Dumont #3 forceps Inox tip size .17 × .10 mm | Roboz | RS-5042 | |
Graefe forceps, 4” (10 cm) long serrated straight, 0.8 mm tip | Roboz | RS-5280 | |
Halstead mosquito forceps, 5" straight, 1.3 mm tips | Roboz | RS-7110 | 2x |
Halstead mosquito forceps, 5" curved, 1.3mm tips | Roboz | RS-7111 | |
Jacobson mosquito forceps 5" curved extra delicate, 0.9 mm tips | Roboz | RS-7117 | |
Kantrowitz forceps, 7.25" 90 degree delicate, 1.7 mm tips | Roboz | RS-7305 | |
Tissue forceps 5", 1X2 teeth, 2 mm tip width | Roboz | RS-8162 | |
Allis-Baby forceps, 12 cm, 4x5 teeth, 3 mm tip width | Fine Science Tools | 11092-12 | 2x |
Adson forceps, 12 cm, serrated, straight | Fine Science Tools | 11006-12 | |
Veterinary electrosurgery handpiece and electrode | MACAN Manufacturing | HPAC-1; R-F11 | |
Surgical Suite Equipment | |||
Circulating warm water blanket and pump | Multiple vendors | Catalog number not available | |
Bair hugger warming unit | 3M | Model 505 | |
IV infusion pump | Heska | Vet IV 2.2 | |
Isoflurane vaporizer and scavenger | Multiple vendors | Catalog number not available | |
Veterinary multi-parameter monitor | Surgivet | Surgivet Advisor | |
Veterinary electrosurgery unit | MACAN Manufacturing | MV-9 | |
Surgical microscope | D.F. Vasconcellos | M900 | 25X magnification for vein graft surgery; 16X magnification for gene transfer surgery |
Zapytaj o uprawnienia na użycie tekstu lub obrazów z tego artykułu JoVE
Zapytaj o uprawnieniaThis article has been published
Video Coming Soon
Copyright © 2025 MyJoVE Corporation. Wszelkie prawa zastrzeżone